Welcome to our dedicated page for NeOnc Technologies Holdings news (Ticker: NTHI), a resource for investors and traders seeking the latest updates and insights on NeOnc Technologies Holdings stock.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc (Nasdaq: NTHI) announced that CEO Amir Heshmatpour has purchased over $500,000 in open-market shares in recent weeks and nearly $1 million over the past year, with additional purchases anticipated. The company completed NEO212 Phase 1 dose escalation and set a recommended Phase 2 dose. The NEO100 Phase 2a trial in recurrent IDH1-mutant high-grade glioma is fully enrolled, with an interim analysis expected later in 2026.
All disclosed purchases were made with personal funds and reported on SEC Form 4 filings.
NeOnc Technologies (NASDAQ:NTHI) disclosed approximately $300,000 of insider purchases by Chairman & CEO Amir Heshmatpour and provided context on 2025 financials and near-term clinical catalysts.
The company reported a $62M net loss for 2025, noted $45.2M of non-cash/non-recurring charges, normalized cash operating expenses of $10.1M, and a subsequent $13.0M private placement in Q1 2026. Key clinical milestones include an interim NEO100 readout ~4 months (~Aug 2026) and a NEO212 Type B FDA meeting within ~4 weeks.
NeOnc Technologies (Nasdaq: NTHI) reported Q4 2025 and full-year updates, highlighting clinical progress and financing to support development. Key points: NEO212 Phase 1 complete with an RP2D of 610 mg; NEO100 Phase 2a fully enrolled with an interim readout expected ~August 2026; PIPE anchored by $10.0M commitment.
Updated NEO100/Phase 1 data showed a 24% radiographic remission rate and 44% six-month PFS; Q4 net loss widened to $62.1M, driven by higher G&A and stock-based compensation.
NeOnc Technologies (Nasdaq: NTHI) appointed David Choi as Chief Accounting Officer effective March 13, 2026. Mr. Choi will oversee accounting, financial reporting, internal controls, and corporate governance as NeOnc advances its Phase 2 clinical programs for central nervous system cancers and expands global operations.
Mr. Choi has more than a decade of experience, previously served as Director at Blythe Global Advisors, held roles at Grant Thornton and Ernst & Young, and is a Certified Public Accountant with graduate and undergraduate degrees from University of California, Irvine.
NeOnc Technologies (NASDAQ:NTHI) focuses on CNS oncology drug delivery. Its lead oral program NEO212 is a next-generation temozolomide designed to improve blood-brain barrier penetration and address MGMT-driven resistance in glioblastoma. Phase 1 dose escalation completed with a Recommended Phase 2 Dose of 610 mg and early signs of disease control observed. Intranasal NEO100 showed Phase 2 radiographic responses and improved progression-free survival versus historical salvage benchmarks. The company also completed a PIPE adding a gross $16.0M to its balance sheet.
NeOnc Technologies (Nasdaq: NTHI) announced Phase 1 dose-escalation results for oral NEO212 on March 4, 2026. The study reached MTD at 810 mg (Cohort 5) after a second dose-limiting toxicity and set the RP2D at 610 mg (Cohort 4).
The Phase 2a metastasis cohort will start at 400 mg. Early safety and tolerability were assessed, and the company reported promising early signs of anti-tumor activity in heavily pretreated GBM and brain metastasis patients. NeOnc intends to request a Type B FDA meeting and submitted required regulatory forms via eCTD.
NeOnc Technologies (Nasdaq: NTHI) will host an investor conference call and webcast on March 4, 2026 at 6:00 a.m. PT / 9:00 a.m. ET to present initial Phase 1 dose‑escalation results from the NEO212-01 trial.
The presentation will cover safety and toxicity data, dose‑escalation observations, pharmacokinetics, and planned regulatory next steps for the oral bioconjugated temozolomide program, with participation from company management and independent Scientific Advisory Board members.
NeOnc Technologies (Nasdaq: NTHI) announced a PIPE financing dated January 30, 2026 to sell up to 2,222,222 shares and five-year warrants to buy up to 2,222,222 shares at a $9.00 exercise price and a combined purchase price of $7.20.
The offering is expected to generate gross proceeds of up to $16 million, including a $10 million lead investment from Cinctive Capital Management. Net proceeds are intended for repayment of indebtedness and for working capital and corporate purposes.
NeOnc Technologies (NASDAQ: NTHI) received an initiation of coverage from Stonegate Capital Partners on January 9, 2026. NeOnc is a clinical-stage life sciences company developing central nervous system therapeutics that aim to overcome the blood-brain barrier, led by its proprietary compound NEO100.
Key program features include a patented synthesis for pharmaceutical-grade purity, an intranasal delivery strategy targeting olfactory and trigeminal pathways, reported favorable tolerability with prolonged dosing, and multiple near-term catalysts: positive Phase 1/2a results announced in December and a NEO100 Phase 2a top-line readout expected mid-2026. The announcement also notes that closing and funding of the Quazar Investment is expected in the near term.
NeOnc Technologies (Nasdaq: NTHI) reported updated clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1-mutant astrocytoma on Dec 15, 2025. The expanded cohort totals 25 patients. Key outcomes: radiographic remission in 24% (6/25), PFS-6 of 44%, and 36% (9/25) alive ≥18 months after treatment start. The company reports no significant toxicity with chronic intranasal dosing. Responses were assessed by RANO criteria and include 1 compassionate-use case, 5 Phase 1, and 18 Phase 2a patients. Management describes the dataset as an important value-inflection point and highlights reproducibility and durability of responses.